# Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

> **NCT05097287** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 1339 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05097287
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-16
- **Primary completion:** 2027-03-16
- **Final completion:** 2029-06-08
- **Target enrollment:** 1339 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05097287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05097287, "Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05097287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*